Liquid biopsy for differential diagnosis of early stage lung cancer, 5/18

May 2018—Integrated Diagnostics announced the e-publication of full results of a large prospective clinical trial validating its Xpresys Lung 2 in *Chest*, titled “Assessment of plasma proteomics biomarker’s ability to distinguish benign from malignant lung nodules: results of the PANOPTIC (PulmonAry NOdule Plasma proTeomIc Classifier) trial” (Silvestri GA, et al. March 1, 2018. doi:10.1016/j.chest.2018.02.012). The clinical validation represents the performance of the Xpresys Lung 2, a second-generation liquid biopsy for the differential diagnosis of early stage lung cancer. The test combines five standard-of-care clinical factors such as patient age and nodule size in combination with the measurement of two proteins, LG3BP and C163A, into a single risk assessment. The validation study confirmed the high accuracy of the XL2 in identifying benign nodules in patients with a pretest probability of malignancy of 50 percent and less.

***Integrated Diagnostics**, 206-576-6300*